ATE552837T1 - Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen - Google Patents

Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen

Info

Publication number
ATE552837T1
ATE552837T1 AT06840105T AT06840105T ATE552837T1 AT E552837 T1 ATE552837 T1 AT E552837T1 AT 06840105 T AT06840105 T AT 06840105T AT 06840105 T AT06840105 T AT 06840105T AT E552837 T1 ATE552837 T1 AT E552837T1
Authority
AT
Austria
Prior art keywords
high dose
immune disorders
treat immune
dose oxazaphosphorine
drugs
Prior art date
Application number
AT06840105T
Other languages
English (en)
Inventor
Robert Brodsky
Richard Jones
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE552837T1 publication Critical patent/ATE552837T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06840105T 2005-12-02 2006-12-04 Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen ATE552837T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74217205P 2005-12-02 2005-12-02
PCT/US2006/061549 WO2007065167A1 (en) 2005-12-02 2006-12-04 Use of high-dose oxazaphosphorine drugs for treating immune disorders

Publications (1)

Publication Number Publication Date
ATE552837T1 true ATE552837T1 (de) 2012-04-15

Family

ID=37898760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06840105T ATE552837T1 (de) 2005-12-02 2006-12-04 Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen

Country Status (6)

Country Link
US (2) US20070202077A1 (de)
EP (2) EP1957082B1 (de)
AT (1) ATE552837T1 (de)
AU (1) AU2006320162B2 (de)
CA (1) CA2631760A1 (de)
WO (1) WO2007065167A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US20070202077A1 (en) * 2005-12-02 2007-08-30 Brodsky Robert A Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008156494A1 (en) * 2006-11-03 2008-12-24 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
US20110123482A1 (en) * 2007-10-01 2011-05-26 The Johns Hopkins University Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009073146A2 (en) * 2007-11-29 2009-06-11 Celgene Corporation Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
JP2011529078A (ja) * 2008-07-25 2011-12-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 自己免疫疾患を治療および予防するための方法および組成物
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
WO2011011706A2 (en) * 2009-07-24 2011-01-27 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
PL405506A1 (pl) * 2013-09-30 2015-04-13 Warszawski Uniwersytet Medyczny Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
EP3171887A1 (de) * 2014-07-24 2017-05-31 Reponex Pharmaceuticals APS Zusammensetzungen mit faktor zur stimulierung von granulozyt-makrophagen-kolonien zur behandlung von entzündlicher darmerkrankung
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
WO2016102530A1 (en) * 2014-12-22 2016-06-30 Bergen Teknologioverføring As Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome
US11395826B2 (en) * 2015-11-20 2022-07-26 Kyushu University, National University Corporation Immunoregulatory agent
US12084495B2 (en) 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction
EP4360714A3 (de) 2016-09-21 2024-07-24 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
MX2020002612A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
US20200077906A1 (en) 2018-09-07 2020-03-12 Augusta University Research Institute, Inc. Method and System for Monitoring Brain Function and Intracranial Pressure
CN119700703A (zh) 2019-01-17 2025-03-28 佐治亚技术研究公司 含有氧化的胆固醇的药物递送系统
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
EP4135760A4 (de) 2020-04-17 2024-04-17 Augusta University Research Institute, Inc. Zusammensetzungen und verfahren zur behandlung von leukämie
CA3228505A1 (en) * 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CN117643588B (zh) * 2023-11-13 2024-11-15 山东天宏生物医药有限公司 呋喃妥因在制备抗类风湿性关节炎药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
US5187266A (en) * 1986-06-30 1993-02-16 Board Of Regents The University Of Texas System Antitumor aldophosphamide glycoside and dideoxyuridine derivatives
US4841085A (en) * 1986-06-30 1989-06-20 Board Of Regents, University Of Texas System Aldophosphamides
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
JP2571119B2 (ja) * 1988-03-08 1997-01-16 株式会社中埜酢店 細胞膜結合型アルデヒド脱水素酸素の構造遺伝子、これを含むプラスミド、形質転換した酢酸菌及び酢酸発酵法
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
US5649904A (en) * 1988-10-07 1997-07-22 Sandoz Ltd. Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
EP1011694A4 (de) * 1996-11-15 2000-11-15 Baxter Int Behandlung zur allogenen stammzelltransplantation
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
US6447767B1 (en) * 1997-05-23 2002-09-10 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
AU1585799A (en) * 1997-11-14 1999-06-07 General Hospital Corporation, The Treatment of hematologic disorders
IL122892A0 (en) * 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
WO1999046392A1 (en) * 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
AU3899199A (en) * 1998-05-12 1999-11-29 Endowment for Research in Human Biology, Inc., The Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
DK1975243T3 (da) * 1998-12-07 2010-06-28 Univ Duke BODIPY-aminoacetaldehyddiethylacetal
US6879959B1 (en) * 2000-01-21 2005-04-12 Quality Care Solutions, Inc. Method of adjudicating medical claims based on scores that determine medical procedure monetary values
WO2001065934A2 (en) * 2000-03-09 2001-09-13 Lee Walters Applications of immune system tolerance to treatment of various diseases
JP2004515453A (ja) * 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
WO2001089509A2 (en) * 2000-05-19 2001-11-29 Thomas Jefferson University Method of treating hiv-1 disease
WO2001091746A1 (en) * 2000-06-01 2001-12-06 The Mclean Hospital Corporation Method for treating alcohol intoxication and alcohol abuse
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
WO2002067968A2 (en) * 2001-02-21 2002-09-06 Emory University 14-3-3 binding molecules as sensitizers for anticancer therapies
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
CN1671373A (zh) * 2002-06-27 2005-09-21 人类生物研究基金公司 用于抑制aldh的化合物
CA2497898C (en) * 2002-09-05 2012-02-07 Bharat Serums & Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna
US7260249B2 (en) * 2002-09-27 2007-08-21 Confirma Incorporated Rules-based approach for processing medical images
WO2004103297A2 (en) * 2003-05-14 2004-12-02 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
AU2005247303A1 (en) * 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-CD20 antibodies
CN101039691B (zh) * 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
US20060253263A1 (en) * 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
JP4837357B2 (ja) * 2005-10-18 2011-12-14 エルピーダメモリ株式会社 半導体記憶装置
US20070202077A1 (en) * 2005-12-02 2007-08-30 Brodsky Robert A Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen

Also Published As

Publication number Publication date
US20110092462A1 (en) 2011-04-21
AU2006320162B2 (en) 2013-07-25
US20070202077A1 (en) 2007-08-30
EP1957082B1 (de) 2012-04-11
EP1957082A1 (de) 2008-08-20
WO2007065167A1 (en) 2007-06-07
EP2345412A1 (de) 2011-07-20
AU2006320162A1 (en) 2007-06-07
CA2631760A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
ATE552837T1 (de) Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
EP1543158A4 (de) Regulierte aptamer-therapeutika
WO2010093993A3 (en) Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
Zarmer et al. Traumatic spinal cord injury: review of the literature
DE602004022284D1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
EP4523750A3 (de) Verfahren zur reduzierung von zerebrovaskulären ereignissen bei patienten mit morbus fabry
Harris FDA dismisses medical benefit from marijuana
Sinha et al. Hemimasticatory spasm: A case report with a new management strategy
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
ATE451145T1 (de) Behandlung von krankheiten
ATE418558T1 (de) Darstellung von 1-aza-2-oxadibenzoäe,hüazulenen und deren verwendung bei der herstellung pharmazeutischer formulierungen zur behandlung und prävention von krankheiten und erkrankungen des zentralen nervensystems
EP4217063A4 (de) Pharmazeutische kombination zur behandlung von menschlichen hypocholinergen störungen
RU2005122896A (ru) Способ оздоровления и коррекции биологического возраста